Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says

Biogen (NASDAQ:BIIB) had its price target boosted by Rothschild & Co Redburn from $150.00 to $180.00 in a report released on Wednesday,MarketScreener reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Rothschild & Co Redburn’s price target would indicate a potential downside of 4.19% from the company’s previous close.

A number of other research firms also recently commented on BIIB. Stifel Nicolaus boosted their price objective on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Canaccord Genuity Group boosted their price objective on shares of Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a report on Wednesday, April 1st. Wells Fargo & Company boosted their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a report on Sunday, February 8th. JPMorgan Chase & Co. boosted their price objective on shares of Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $185.00 to $225.00 in a report on Wednesday. Fourteen research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $211.31.

Biogen Price Performance

Shares of BIIB opened at $187.88 on Wednesday. Biogen has a twelve month low of $115.25 and a twelve month high of $202.41. The stock’s 50 day moving average is $185.37 and its two-hundred day moving average is $174.82. The firm has a market capitalization of $27.57 billion, a PE ratio of 21.33, a P/E/G ratio of 2.54 and a beta of 0.16. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts anticipate that Biogen will post 15.75 earnings per share for the current year.

Insider Activity

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Reflection Asset Management purchased a new position in shares of Biogen during the 4th quarter worth $25,000. WPG Advisers LLC raised its stake in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the period. First Horizon Corp purchased a new position in Biogen during the fourth quarter worth approximately $30,000. Root Financial Partners LLC raised its stake in Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 123 shares during the period. Finally, MV Capital Management Inc. purchased a new position in Biogen during the fourth quarter worth approximately $34,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225, citing a “slew of pipeline catalysts” over the next 12–15 months that could materially boost revenue and valuation. Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027
• Neutral Sentiment: Several analysts issued mixed takes — some raising targets but keeping neutral ratings, which suggests upside is acknowledged but not consensus conviction. This readjusts expectations without flipping broad buy/sell positioning. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB)…
• Neutral Sentiment: JPMorgan raised its price target to $185 but kept a Neutral rating — marginally higher valuation support but still limited upside per their view. MarketScreener: JPMorgan adjusts price target on Biogen to $185
• Neutral Sentiment: Rothschild & Co Redburn raised its target to $180 but kept a Neutral rating — another example of price‑target lift without a buy endorsement. MarketScreener: Rothschild & Co Redburn adjusts Biogen price target to $180
• Neutral Sentiment: Jim Cramer noted he’s “reopening the file” on Biogen after recent coverage and upgrades — a media boost that can support short‑term interest but isn’t an analyst endorsement. Jim Cramer Says “I Got to Reopen the File on Biogen”
• Negative Sentiment: Wolfe Research trimmed its Q1 2026 EPS estimate (from $2.79 to $2.64) even as it nudged FY‑2027 estimates higher — the near‑term cut can pressure the stock ahead of earnings.
• Negative Sentiment: HSBC reiterated a Reduce rating and uses a $150 target — a markedly lower anchor than UBS and others, which can prompt selling by investors who follow conservative sell‑side views. What is HSBC’s Estimate for Biogen Q1 Earnings?
• Neutral Sentiment: Barclays reaffirmed its Hold rating — another stabilizing but non‑bullish stance. Barclays Reaffirms Their Hold Rating on Biogen (BIIB)

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.